Observational studyInternal and emergency medicine2026
Impact of age on the prognostic benefit of follow-up in UMIPIC units: analysis of the RICA registry.
Observational study in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidisciplinary management programs are recommended for patients with heart failure (HF), yet it remains uncertain whether their prognostic benefits extend uniformly across all ages, particularly among the very elderly. This study evaluated whether age modifies the benefit of follow-up in UMIPIC (Comprehensive Management Unit for Patients with Heart Failure), using data from the Spanish RICA registry. We conducted a prospective, multicenter cohort study including 5644 patients (mean age 79.9±8.6 years; 52.7% women) hospitalized for acute HF and followed for one year. Patients were managed either within UMIPIC units or with conventional care. The primary outcomes were all-cause mortality and HF readmissions. Cox regression models tested the interaction between UMIPIC and age, modeled categorically (<90 vs ≥90 years), continuously, and with restricted cubic splines. During a median follow-up of 363 days, 1.419 patients (25.1%) died and 1.287 (22.8%) were rehospitalized for HF. In multivariable Cox models, UMIPIC participation was independently associated with lower mortality, with a significant age interaction (p=0.026). Among patients, 90 years, UMIPIC follow-up reduced mortality by 40% (HR 0.60; 95% CI 0.50-0.73; p<0.001), with consistent benefit across age groups (p for interaction=0.971). UMIPIC follow-up was associated with lower mortality and rehospitalization in older adults with HF. The survival benefit was most pronounced among nonagenarians, supporting the inclusion of very old patients in multidisciplinary HF programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.